Insmed Incorporated Common Stock (INSM)
Stock · NASDAQ · Health Care
$96.28as of 10/16/2026
Price chart
Active signals
INSM Signal Track Record
How signals performed across all stocks →What INSM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +0.5% | 54% | October 5, 2026 |
| Bollinger Band Breakdown | 26 | +3.3% | 69% | October 1, 2026 |
| Bollinger Band Breakout | 26 | -1.7% | 46% | August 6, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -3.0% | 38% | April 13, 2026 |
| Any 20-session window (baseline) | +0.9% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INSM
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1,664
- Website
- insmed.com/
Fundamentals
- 1-day range
- $97.9$100.72
- Market cap
- $28.73B
- P/E (trailing)
- —
- P/E (forward)
- 131.95
- EPS (trailing)
- $-4.10
- Dividend yield
- —
- Beta
- 0.82
- Avg. volume
- 2.60M
How Insmed Incorporated Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Feb 20, 2025 · via SEC EDGAR / Finnhub
Forecasts
22 analyst ratings
Insmed Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- INSMInsmed Incorporated Common Stock$96.27▼ 2.96%Market cap $28.73BP/E —$90.39$212.75
- ALNYAlnylam Pharmaceuticals Inc. Common Stock$231.83▼ 0.94%Market cap $28.92BP/E 37.17$197.81$495.55
- ROIVRoivant Sciences Ltd. Common Shares$33.53▼ 1.50%Market cap $25.38BP/E —$15.9$42.5
- ZTSZoetis Inc. Class A Common Stock$79.38▲ 1.22%Market cap $32.39BP/E 12.43$68.77$148.3
- RPRXRoyalty Pharma plc Class A Ordinary Shares$60.96▲ 2.25%Market cap $32.97BP/E 41.57$35.23$64.38
- UTHRUnited Therapeutics Corporation Common Stock$533.12▼ 1.55%Market cap $22.62BP/E 17.78$409.07$609.35
- ONCBeOne Medicines Ltd. American Depositary Shares$369.06▼ 1.34%Market cap $36.67BP/E 61.27$205.51$319.24
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INSM Insmed Incorporated Common Stock | $28.73B | — | $96.27 | ▼ 2.96% | $90.39$212.75 |
| ALNY Alnylam Pharmaceuticals Inc. Common Stock | $28.92B | 37.17 | $231.83 | ▼ 0.94% | $197.81$495.55 |
| ROIV Roivant Sciences Ltd. Common Shares | $25.38B | — | $33.53 | ▼ 1.50% | $15.9$42.5 |
| ZTS Zoetis Inc. Class A Common Stock | $32.39B | 12.43 | $79.38 | ▲ 1.22% | $68.77$148.3 |
| RPRX Royalty Pharma plc Class A Ordinary Shares | $32.97B | 41.57 | $60.96 | ▲ 2.25% | $35.23$64.38 |
| UTHR United Therapeutics Corporation Common Stock | $22.62B | 17.78 | $533.12 | ▼ 1.55% | $409.07$609.35 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $36.67B | 61.27 | $369.06 | ▼ 1.34% | $205.51$319.24 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Wolfe Research Downgrades Insmed to Peer Performbenzinga · 10/12/2026
- Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative?Yahoo · 10/8/2026
- Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trialYahoo · 10/7/2026
- INSM Stock Slides on CFO Exit, Reiterates '26 Sales ViewYahoo · 10/6/2026
- $100 Invested In Insmed 5 Years Ago Would Be Worth This Much TodayBenzinga · 10/5/2026
- Insmed stock falls as CFO Sara Bonstein to step downYahoo · 10/5/2026
- Nasdaq 100 Hits Record, Brazil's EWZ Soars 13%: Stock Market TodayBenzinga · 10/5/2026
- Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance ReaffirmedBenzinga · 10/5/2026
- Insmed Announces CFO TransitionYahoo · 10/5/2026
Insider Activity
Insider Actions →- David R. Brennan · September 9, 2026 · Sale25.0K @ $124
- Melvin Sharoky, MD · August 17, 2026 · Sale5.0K @ $127.53
- Roger Adsett · August 10, 2026 · Option Exercise81.0K @ $30.46
- Roger Adsett · August 10, 2026 · Option Exercise82.3K @ $13.67
- Roger Adsett · August 10, 2026 · Sale239.8K @ $133.27
- Roger Adsett · August 10, 2026 · Option Exercise76.6K @ $17.16
- Martina M.D. Flammer · August 6, 2026 · Option Exercise8.9K @ $25.83
- Martina M.D. Flammer · August 6, 2026 · Option Exercise18.3K @ $18.95
- Martina M.D. Flammer · August 6, 2026 · Sale18.3K @ $129.4
- Martina M.D. Flammer · August 6, 2026 · Sale8.9K @ $127
- William Lewis · July 23, 2026 · Option Exercise4.4K @ $17.16
- William Lewis · July 23, 2026 · Option Exercise6.3K @ $30.46
- William Lewis · July 23, 2026 · Sale5.9K @ $106.43
- William Lewis · July 23, 2026 · Sale4.8K @ $105.62
- William Lewis · July 9, 2026 · Option Exercise4.4K @ $17.16
Institutional Ownership
March 31, 2026
- Total shares held
- 183.14M
- Total value held
- $28.58B
- Institutional holders
- 663
- Unknown16.81M
- Unknown16.68M
- Unknown13.16M
- Unknown9.64M
- Unknown7.42M
- Unknown6.53M
- Unknown5.64M
- Unknown5.60M
- Unknown5.55M
- Unknown4.84M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Wolfe Research Downgrades Insmed to Peer Perform Ahead of CHEST 2026
Wolfe Research lowered its rating on Insmed to Peer Perform, joining a wave of recent analyst downgrades. This move comes as the company prepares to present new data for its respiratory portfolio, including the Phase 3 PALM program, at the CHEST 2026 conference. While the stock is currently trading near its 52-week low, other analysts like HC Wainwright remain bullish with a $220 price target.
Wolfe Research Downgrades Insmed to Peer Perform Ahead of CHEST 2026. Wolfe Research lowered its rating on Insmed to Peer Perform, joining a wave of recent analyst downgrades. This move comes as the company prepares to present new data for its respiratory portfolio, including the Phase 3 PALM program, at the CHEST 2026 conference. While the stock is currently trading near its 52-week low, other analysts like HC Wainwright remain bullish with a $220 price target.